Xeris Biopharma Holdings (XERS) Treasury Shares (2020 - 2026)

Xeris Biopharma Holdings' Treasury Shares history runs 7 years deep, the most recent figure standing at $9.7 million for Q1 2026.

• Quarterly Treasury Shares fell 36.04% year-over-year to $9.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (down 36.04% YoY) and the FY2025 annual result came in at $13.5 million, down 17.72% from the prior year.
• Treasury Shares was $9.7 million for Q1 2026 at Xeris Biopharma Holdings, down from $13.5 million in the prior quarter.
• Across five years, Treasury Shares topped out at $16.4 million in Q4 2024 and bottomed at $5.3 million in Q4 2022.
• A 5-year average of $12.5 million and a median of $13.6 million in 2025 frame the typical range for Treasury Shares.
• Annual changes were most pronounced in 2023 — Treasury Shares surged 120.33% — and 2026, when it plunged 36.04%.
• Xeris Biopharma Holdings' Treasury Shares stood at $5.3 million in 2022, then jumped by 120.33% to $11.6 million in 2023, then soared by 41.81% to $16.4 million in 2024, then slipped by 17.72% to $13.5 million in 2025, then dropped by 28.38% to $9.7 million in 2026.
• Business Quant data shows XERS's Treasury Shares at $9.7 million in Q1 2026, $13.5 million in Q4 2025, and $13.8 million in Q3 2025.